COVID-19 Response Fund Boosts SMHS Research Efforts
The Lynch Lab is currently part of the research initiative at GWU that measures the durability of the antibody response to COVID-19 in the Washington, D.C. area.
GWSMHS, Oct 2020
GW Researcher Awarded $3.6M to Investigate HIV Antibody Treatments
The National Institutes of Health has awarded $3.6 million to Rebecca Lynch, PhD, assistant professor of microbiology, immunology, and tropical medicine at the George Washington University School of Medicine and Health Sciences, to investigate HIV-1 resistance to antibody treatments.
GWSMHS, July 2020
Clara Bliss Hinds Society for Women in Medicine and Health Sciences
Dr. Rebecca Lynch serves as Treasurer of The Clara Bliss Hinds Society, the George Washington University School of Medicine and Health Sciences Group on Women in Medicine and Science.
New R21 Awarded to DC CFAR Investigator, Rebecca Lynch, PhD
DC CFAR investigator, Rebecca Lynch, PhD, was recently awarded an R21 from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) entitled, "Effects of Boosting Mucosal Immunity by Microbiota Manipulation on B Cell Responses to the HIV-1 Vaccine". This grant builds on work from Dr. Lynch's CFAR Pilot Award, "Elucidating the commensal-HIV reactive antibody repertoire in Rhesus macaques."
DC CFAR, Feb 2019
New Antibody Treatment for HIV Passes First Hurdle
An experimental treatment providing a new approach in the fight against HIV has cleared the first hurdle.
VoA News, Dec 2015
A New HIV Treatment? Antibody Infusion Supresses The Virus In Real-Life Patients
A pilot study finds that the antibody VRC01 may have potential in reducing the viral load of people living with HIV. It’s no cure, but it might someday lend much needed support in our war against HIV.
Medical Daily, Dec 2015
Immune responses may inhibit antibody-based treatments for HIV
Researchers from the Medical University of South Carolina recently conducted studies to determine whether immune responses inhibit the results of broadly neutralizing antibody treatments that may help people with HIV infections.
Vaccine News, Dec 2015
HIV antibody curbs virus in trial
A new medicine to control HIV infection may soon become available, if promising results from a Phase 1 clinical trial are confirmed.
The San Diego Union-Tribune, Dec 2015
New HIV Treatment Shows Promise in Early Research
Preliminary new research raises the prospect that a recently discovered antibody - an important component of the immune system - could be enlisted to boost the body's response to HIV, the virus that causes AIDS.
Health Day, Dec 2015